Literature DB >> 16939674

Antiarrhythmic drug therapy.

Brian R Triola1, Peter R Kowey.   

Abstract

The use of antiarrhythmic drugs can be challenging to physicians. They are effective in treating various types of arrhythmias, yet their potential to cause adverse events, in particularly proarrhythmia, can be intimidating. When the decision to use antiarrhythmic therapy has been made, physicians are confronted with several issues: choosing the right drug, preventing complications, and selecting the setting in which the drug is to be given (in-hospital vs outpatient). In determining the best antiarrhythmic agent for each patient, one should have a basic understanding of their mechanisms of action and indications. Once this decision has been made, attention turns to avoiding complications and assessing for efficacy. Clinicians should be aware of the common drug interactions of each antiarrhythmic agent and avoid these whenever possible. In addition, patients need meticulous follow-up, including serial electrocardiograms and assessment for cardiovascular side effects. For several of the antiarrhythmic drugs, this can be accomplished in the outpatient setting in appropriate patients.

Entities:  

Year:  2006        PMID: 16939674     DOI: 10.1007/s11936-006-0040-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  38 in total

1.  Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology.

Authors:  N Goldschlager; A E Epstein; G Naccarelli; B Olshansky; B Singh
Journal:  Arch Intern Med       Date:  2000-06-26

Review 2.  Clinical safety profile of sotalol in patients with arrhythmias.

Authors:  L F Soyka; C Wirtz; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

3.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

4.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

5.  Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients.

Authors:  E Aliot; L De Roy; A Capucci; J Hernández; I Denjoy; J M Lupoglazoff; P Coumel
Journal:  Ann Cardiol Angeiol (Paris)       Date:  2003-02

6.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

7.  Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone.

Authors:  C S Stavens; B McGovern; H Garan; J N Ruskin
Journal:  Am Heart J       Date:  1985-07       Impact factor: 4.749

8.  Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.

Authors:  R F Kehoe; T A Zheutlin; C S Dunnington; T A Mattioni; G Yu; R B Spangenberg
Journal:  Am J Cardiol       Date:  1990-01-02       Impact factor: 2.778

9.  Usefulness of sotalol for life-threatening ventricular arrhythmias.

Authors:  D M Roden
Journal:  Am J Cardiol       Date:  1993-08-12       Impact factor: 2.778

Review 10.  Clinical pharmacology of antiarrhythmic drugs.

Authors:  A Capucci; D Aschieri; G Q Villani
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.